about
Intracellular targeting with engineered proteinsBispecific antibodies and their applicationsChallenges in Antibody Development against Tn and Sialyl-Tn AntigensFc gamma receptors: glycobiology and therapeutic prospectsSelecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane ProteinsAdvances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-lifeKey factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and developmentSupercritical carbon dioxide design strategies: from drug carriers to soft killersB Cell-Based Seamless Engineering of Antibody Fc DomainsPredicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey.Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody.Role of Homologous Fc Fragment in the Potency and Efficacy of Anti-Botulinum Antibody PreparationsFc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds.Weak protein interactions and pH- and temperature-dependent aggregation of human Fc1.Directed evolution of human scFvs in DT40 cells.Swift antibodies to counter emerging viruses.Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.Bench to Bedside: Stability Studies of GMP Produced Trastuzumab-TCMC in Support of a Clinical Trial.A Combinatory Antibody-Antigen Microarray Assay for High-Content Screening of Single-Chain Fragment Variable Clones from Recombinant Libraries.Evaluating the expression profile and stability of different UCOE containing vector combinations in mAb-producing CHO cellsNext-generation sequencing enables the discovery of more diverse positive clones from a phage-displayed antibody library.Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17.Computationally Designed Bispecific Antibodies using Negative State Repertoires.Technological advances in precision medicine and drug development.A comparison of biophysical characterization techniques in predicting monoclonal antibody stability.Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma.Gene therapy using plasmid DNA-encoded anti-HER2 antibody for cancers that overexpress HER2.Ig-like domain 6 of VCAM-1 is a potential therapeutic target in TNFα-induced angiogenesisApplicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope.Aptamers as targeted therapeutics: current potential and challenges.The present state of the art in expression, production and characterization of monoclonal antibodies.Rapid and accurate in silico solubility screening of a monoclonal antibody library.Therapeutic monoclonal antibodies and clinical laboratory tests: When, why, and what is expected?Quantitative MS analysis of therapeutic mAbs and their glycosylation for pharmacokinetics study.Statistical characterization of therapeutic protein modifications.Monoclonal antibodies: technologies for early discovery and engineering.Elastin-like polypeptides: Therapeutic applications for an emerging class of nanomedicines.Long-term direct visualization of passively transferred fluorophore-conjugated antibodies.Preferential interactions of trehalose, L-arginine.HCl and sodium chloride with therapeutically relevant IgG1 monoclonal antibodies.Overview on biotherapeutic proteins: impact on bioanalysis.
P2860
Q26740106-0A37FD9D-2205-46D5-88CB-BB23E8CFEFCBQ26774024-BF4EE81D-D795-4D20-9D22-8FED1076C54FQ26798183-F56F90C7-C40D-406E-8911-D2BB5DB07DD9Q28076303-C4B272BE-B761-46A0-9147-C1D10ACD2032Q28077999-906809D1-113C-4C02-A2EA-8A8E5A70FE0AQ28079016-43612235-0A63-4FE8-838F-B44752F92844Q28082880-ED8FD14A-6CCA-4808-AF4C-82D317BE9DA7Q28085090-4C4F33A4-50D2-4F89-AE01-EF3B86AC7B9FQ28554659-DA60B44F-F3EA-4FCD-B3C4-EB40FD401C5FQ31091923-554E6F00-2CF0-4E6E-910C-1C21FB207035Q31814859-9D0AF0FD-BDEC-4274-87C2-CBD583B439A4Q33845127-ADCBB2FC-8DE3-431D-9770-B099DB97BC26Q34550963-93BE74A9-2128-43A9-B296-DC9377D76683Q35743857-0FD36750-350C-4214-8F10-C278456A820EQ35828141-AF85A558-AA9F-4EBA-BA01-019FD4A9FEA4Q35989719-2DAA1858-C74D-44F7-8246-5ACE0AB45A15Q36023082-9B99D566-F762-447B-AC6C-46D1BB6AF0C7Q36105805-1EB75EE8-0E7F-4D63-90FD-9F78DC1D3884Q36230548-B6576080-2D1D-4A3B-93BD-4A8BF7233FF8Q36287706-140AA134-C088-40AF-BB1F-29C76596E701Q36321367-0DE7F239-6249-4C7D-8830-03060A8E50EDQ36599623-4F038FC9-7892-48E2-BD0D-7D2FECEF6E8AQ36899812-19999628-7F79-48F6-8FA9-A94E43A7E1CCQ37244501-D6FE5982-546B-450A-A5DD-AC4153BCA29DQ37287010-C5270D15-A494-448B-9538-05C67F614EB6Q37376659-618A0012-B430-415D-A2E1-F23D71ED34EDQ37393751-3B584DC7-7036-4674-87DD-DAA6387AE1AFQ37680056-E6C0AFCC-D39E-4580-A092-027FBD10E8DDQ37719187-42EC1780-0045-40BE-8085-FC83B421920DQ38290290-CED313B5-9EF4-4DF4-BAF6-010AFE8BABC8Q38572163-95AD130E-0FA8-4B41-B33B-8F8FF1D2E87BQ38622959-F5628A6B-2C30-41C9-B955-1A01D0EFB5EAQ38623790-CEF5C81A-7EE7-4EA8-BC36-5588D77E2ED5Q38628086-3289A0A7-5B7B-40B2-BA57-2DB1D44FB330Q38628116-372FBCDA-B355-44D0-AC82-FA2BC80992EBQ38633596-1C5E44C5-1A3B-46F9-93CC-5C6B8616C4F5Q38636559-12225833-6517-4C24-A4B5-22696A2573ABQ38646491-4A2160B7-3B27-493E-91AA-2383E268FC2AQ38652096-4038406E-2E18-4701-BE90-BD0E4FA3E7E1Q38663214-2D8922A4-CF2D-4955-B044-5E7BDBD194BB
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The therapeutic monoclonal antibody market.
@en
type
label
The therapeutic monoclonal antibody market.
@en
prefLabel
The therapeutic monoclonal antibody market.
@en
P2093
P2860
P1476
The therapeutic monoclonal antibody market.
@en
P2093
Dawn M Ecker
Howard L Levine
Susan Dana Jones
P2860
P356
10.4161/19420862.2015.989042
P577
2015-01-01T00:00:00Z